Kahira Pharmaceuticals & Chemical Industries Company (EGX: CPCI)
Egypt
· Delayed Price · Currency is EGP 84.00
0.00 (0.00%)
At close: Oct 13, 2024
CPCI Income Statement
Financials in millions EGP. Fiscal year is July - June.
Millions EGP. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | Jun '19 Jun 30, 2019 | 2018 - 2014 |
| Revenue | 1,385 | 1,005 | 1,112 | 1,062 | 1,010 | 962.94 | Upgrade
|
| Revenue Growth (YoY) | 25.33% | -9.61% | 4.71% | 5.11% | 4.93% | 11.59% | Upgrade
|
| Cost of Revenue | 929.24 | 767.94 | 785.17 | 793.91 | 750.02 | 733.31 | Upgrade
|
| Gross Profit | 455.57 | 237.3 | 326.95 | 268.13 | 260.41 | 229.64 | Upgrade
|
| Selling, General & Admin | 108.94 | 103.76 | 101.75 | 87.62 | 98.97 | 107.96 | Upgrade
|
| Other Operating Expenses | 56.92 | 56.8 | 33.11 | 24.18 | 22.67 | 16.53 | Upgrade
|
| Operating Expenses | 165.86 | 160.56 | 134.86 | 111.8 | 121.64 | 124.48 | Upgrade
|
| Operating Income | 289.71 | 76.74 | 192.08 | 156.33 | 138.77 | 105.15 | Upgrade
|
| Interest Expense | -16.62 | -3.47 | - | - | - | - | Upgrade
|
| Interest & Investment Income | 10.95 | 4.36 | 6.87 | 3.89 | 3.15 | 6.37 | Upgrade
|
| Currency Exchange Gain (Loss) | -24.63 | - | - | - | -2.1 | -3.52 | Upgrade
|
| Other Non Operating Income (Expenses) | 51.76 | 49.93 | 15.14 | 2.84 | 2.96 | 2.35 | Upgrade
|
| EBT Excluding Unusual Items | 311.17 | 127.56 | 214.1 | 163.06 | 142.77 | 110.36 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.1 | - | - | - | -0.01 | 0.22 | Upgrade
|
| Other Unusual Items | - | - | - | - | -1.37 | -1.35 | Upgrade
|
| Pretax Income | 311.07 | 127.56 | 214.1 | 163.06 | 141.39 | 109.23 | Upgrade
|
| Income Tax Expense | 74.96 | 30.47 | 48.35 | 38.75 | 32.25 | 24.06 | Upgrade
|
| Earnings From Continuing Operations | 236.11 | 97.09 | 165.74 | 124.3 | 109.14 | 85.17 | Upgrade
|
| Net Income | 236.11 | 97.09 | 165.74 | 124.3 | 109.14 | 85.17 | Upgrade
|
| Net Income to Common | 236.11 | 97.09 | 165.74 | 124.3 | 109.14 | 85.17 | Upgrade
|
| Net Income Growth | 40.93% | -41.42% | 33.34% | 13.89% | 28.14% | -21.47% | Upgrade
|
| Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 15 | 15 | Upgrade
|
| Shares Outstanding (Diluted) | 15 | 15 | 15 | 15 | 15 | 15 | Upgrade
|
| EPS (Basic) | 15.81 | 6.50 | 11.10 | 8.32 | 7.31 | 5.70 | Upgrade
|
| EPS (Diluted) | 15.81 | 6.50 | 11.10 | 8.32 | 7.31 | 5.70 | Upgrade
|
| EPS Growth | - | -41.42% | 33.34% | 13.89% | 28.14% | -21.47% | Upgrade
|
| Free Cash Flow | 12.21 | 9.45 | 34.52 | 138.57 | -30.3 | 113.4 | Upgrade
|
| Free Cash Flow Per Share | 0.82 | 0.63 | 2.31 | 9.28 | -2.03 | 7.59 | Upgrade
|
| Dividend Per Share | 5.000 | 5.000 | 5.000 | 4.000 | 2.680 | - | Upgrade
|
| Dividend Growth | 0% | 0% | 25.00% | 49.25% | - | - | Upgrade
|
| Gross Margin | 32.90% | 23.61% | 29.40% | 25.25% | 25.77% | 23.85% | Upgrade
|
| Operating Margin | 20.92% | 7.63% | 17.27% | 14.72% | 13.73% | 10.92% | Upgrade
|
| Profit Margin | 17.05% | 9.66% | 14.90% | 11.70% | 10.80% | 8.84% | Upgrade
|
| Free Cash Flow Margin | 0.88% | 0.94% | 3.10% | 13.05% | -3.00% | 11.78% | Upgrade
|
| EBITDA | 318.85 | 88.3 | 207.25 | 156.77 | 139.42 | 115.84 | Upgrade
|
| EBITDA Margin | 23.02% | 8.78% | 18.64% | 14.76% | 13.80% | 12.03% | Upgrade
|
| D&A For EBITDA | 29.14 | 11.56 | 15.17 | 0.44 | 0.65 | 10.69 | Upgrade
|
| EBIT | 289.71 | 76.74 | 192.08 | 156.33 | 138.77 | 105.15 | Upgrade
|
| EBIT Margin | 20.92% | 7.63% | 17.27% | 14.72% | 13.73% | 10.92% | Upgrade
|
| Effective Tax Rate | 24.10% | 23.88% | 22.58% | 23.77% | 22.81% | 22.03% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.